Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

Brian J. Druker

doi:10.1038/sj.onc.1206081

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

Brian J. Druker

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Original language	English (US)
Pages (from-to)	8541-8546
Number of pages	6
Journal	Oncogene
Volume	21
Issue number	56 REV. ISS. 7
DOIs	https://doi.org/10.1038/sj.onc.1206081
State	Published - Dec 9 2002

Keywords

Bcr-Abl
CML
Inhibitor
STI571
Tyrosine kinase

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/sj.onc.1206081

Cite this

@article{f25f6ac522174acf90a8fd19009fca18,

title = "Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML",

keywords = "Bcr-Abl, CML, Inhibitor, STI571, Tyrosine kinase",

author = "Druker, {Brian J.}",

year = "2002",

month = dec,

day = "9",

doi = "10.1038/sj.onc.1206081",

language = "English (US)",

volume = "21",

pages = "8541--8546",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "56 REV. ISS. 7",

}

TY - JOUR

T1 - Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

AU - Druker, Brian J.

PY - 2002/12/9

Y1 - 2002/12/9

KW - Bcr-Abl

KW - CML

KW - Inhibitor

KW - STI571

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=0037049772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037049772&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206081

DO - 10.1038/sj.onc.1206081

M3 - Article

C2 - 12476300

AN - SCOPUS:0037049772

SN - 0950-9232

VL - 21

SP - 8541

EP - 8546

JO - Oncogene

JF - Oncogene

IS - 56 REV. ISS. 7

ER -

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this